Childhood cancers trials in Germany

In Germany 143 Also abroad 2459

143 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Augsburg, Essen, Hamburg, Heidelberg, Mannheim
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Berlin, Düsseldorf, Freiburg im Breisgau, München, Würzburg
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Where
Berlin, Bonn, Essen, Hamburg, Leipzig
Age
15 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00
Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Erlangen, Frankfurt am Main, Hamburg
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 4Taking people
Asciminib Roll-over Study
Where
Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Berlin, Munich, Ulm
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Cologne, Frankfurt Am Main, Grosshansdorf, Heidelberg
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 1Taking people
A Phase I Dose Finding Study of MB-CART2219.1
Where
Tuebingen
Age
12 years to 75 years
People
36
Run by
University Hospital Tuebingen
See details and how to joinNCT07108868 · EU 2024-516838-35-00
Phase 1/2Taking people
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Münster
Age
6 months to 30 years
People
65 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05533775
Phase 3Taking people
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Where
Muenster
Age
1 year to 64 years
People
130 worldwide
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00
Phase 1/2Taking people
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Muenster
Age
Up to 17 years
People
37 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00
No phaseTaking people
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
Where
Aschaffenburg, Bergisch Gladbach, Erlangen, Esslingen am Neckar, Itzehoe, Kulmbach, Lübeck, Wilhelmshaven
People
257
Run by
Institut fuer Frauengesundheit
See details and how to joinNCT07521202
Phase 1Not yet taking people in Germany
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Where
Münster
Age
1 year to 25 years
People
30
Run by
Universität Münster
See details and how to joinNCT07897968
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Berlin, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Karlsruhe, Magdeburg, Munich, Regensburg, Tuebingen, Ulm, Wuerzburg
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
No phaseNot yet taking people in Germany
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
Where
Berlin, München
People
50 worldwide
Run by
Aristotle University Of Thessaloniki
See details and how to joinNCT07888322
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Berlin, Cologne, Giessen, Muenster, Tuebingen
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1/2Taking people
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Where
Berlin, Cologne, Muenster
Age
1 month to 17 years
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00
No phaseTaking people
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Where
Erlangen
Age
3 years and over
People
180
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07705178
No phaseTaking people
Met Non Small Cell Cancer Registry (MOMENT)
Where
Chemnitz, Großhansdorf, Heidelberg, Löwenstein
People
700 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Aachen, Greifswald, Halle, Rostock
Age
6 years and over
People
4,000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Berlin
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 2Taking people
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Where
Heidelberg
Age
12 months to 39 years
People
60 worldwide
Run by
Nationwide Children's Hospital
See details and how to joinNCT06838676
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Brunswick, Cologne, Cottbus, Datteln, Dortmund, Dresden, Düsseldorf, Erfurt, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Göttingen, Halle (Saale), Hamburg, Hanover, Heidelberg, Herdecke, Homburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Krefeld, Leipzig, Lübeck, Magdeburg, Mainz, Mannheim, Minden, Munich, Münster, Nürnberg, Oldenburg, Ratisbon, Rostock, Stuttgart, Tuebingen, Ulm, Wuerzburg
Age
Up to 17 years
People
137 worldwide
Run by
GPOH gGmbH
See details and how to join2022-501454-11-00 · EU 2022-501454-11-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Brunswick, Chemnitz, Duesseldorf, Hamburg, Heidelberg, Herne, Jena, Leipzig, Minden, Stuttgart, Tuebingen
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00